Functional CD3


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
10 2019
Historique:
received: 15 03 2019
accepted: 01 04 2019
pubmed: 19 5 2019
medline: 12 8 2020
entrez: 19 5 2019
Statut: ppublish

Résumé

The changes in T cell subsets and programmed death ligand 1 (PD-L1) expression during the transition from ductal carcinoma in situ (DCIS) to early invasive breast cancer had not been well studied. A total of 85 DCIS patients were classified into 49 DCIS (clinical stage: Tis, noninvasive) and 36 with a minimally infiltrating lesion (MIL; < 5 mm; clinical stage: T1a). We explored the quantitative alterations of T-cell markers and PD-L1 in these groups using the Opal multi-immunohistochemistry technique. We observed increased infiltration of CD3-positive (CD3 We conclude that during the transition from DCIS to an invasive lesion, the host cytolytic T cells begin interacting with the tumor and destroy the tumor tissue, leading to an adaptive upregulation of PD-L1 and tumor protection against immune destruction.

Sections du résumé

BACKGROUND
The changes in T cell subsets and programmed death ligand 1 (PD-L1) expression during the transition from ductal carcinoma in situ (DCIS) to early invasive breast cancer had not been well studied.
PATIENTS AND METHODS
A total of 85 DCIS patients were classified into 49 DCIS (clinical stage: Tis, noninvasive) and 36 with a minimally infiltrating lesion (MIL; < 5 mm; clinical stage: T1a). We explored the quantitative alterations of T-cell markers and PD-L1 in these groups using the Opal multi-immunohistochemistry technique.
RESULTS
We observed increased infiltration of CD3-positive (CD3
CONCLUSION
We conclude that during the transition from DCIS to an invasive lesion, the host cytolytic T cells begin interacting with the tumor and destroy the tumor tissue, leading to an adaptive upregulation of PD-L1 and tumor protection against immune destruction.

Identifiants

pubmed: 31101455
pii: S1526-8209(19)30213-7
doi: 10.1016/j.clbc.2019.04.001
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
CD3 Complex 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e617-e623

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Shuzhen Lv (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Department of Breast Surgical Oncology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Shuo Wang (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Guoliang Qiao (G)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Xiaoli Wang (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Xinna Zhou (X)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Fengcai Yan (F)

Department of Pathology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Yanping Li (Y)

Department of Breast Surgical Oncology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Suya Wang (S)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

Michael A Morse (MA)

Department of Medicine, Duke University Medical Center, Durham, NC; Department of Surgery, Duke University Medical Center, Durham, NC.

Amy Hobeika (A)

Department of Surgery, Duke University Medical Center, Durham, NC.

Jun Ren (J)

Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: jun.ren@duke.edu.

Herbert Kim Lyerly (HK)

Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: kim.lyerly@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH